Page 581«..1020..580581582583..590600..»

Comparison of Patterns of Coronary Artery Disease in Patients with Heart Failure by Cardiac Amyloidosis Status – DocWire News

Posted: Published on October 8th, 2020

Background/purpose:The aim of this study is to characterize the pattern and the severity of coronary artery lesions in cardiac amyloidosis. Continue reading

Posted in Myocardial Infarction | Comments Off on Comparison of Patterns of Coronary Artery Disease in Patients with Heart Failure by Cardiac Amyloidosis Status – DocWire News

Impact of the COVID-19 pandemic on coronary invasive procedures at two Italian high-volume referral centers – DocWire News

Posted: Published on October 8th, 2020

This article was originally published here J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):869-873 Continue reading

Posted in Myocardial Infarction | Comments Off on Impact of the COVID-19 pandemic on coronary invasive procedures at two Italian high-volume referral centers – DocWire News

FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate – Targeted Oncology

Posted: Published on October 8th, 2020

The FDA has granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms (BPDCN), ImmunoGen, Inc., announced in a press release. We are pleased FDA has granted Breakthrough Therapy designation for IMGN632, our novel CD123-targeted ADC, as it underscores the urgent need for effective and well-tolerated treatments for patients with this rare and aggressive cancer, said Mark Enyedy, president and chief executive officer, ImmunoGen, in a statement. We look forward to continuing to work with FDA to further define the development path for IMGN632 in BPDCN, in addition to pursuing our ongoing evaluation of IMGN632 in AML and other hematological malignancies. Continue reading

Posted in Myocardial Infarction | Comments Off on FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate – Targeted Oncology

Matthew T. Mangino: Commission reports on COVID-19 and criminal justice – The Times

Posted: Published on October 8th, 2020

opinion Matthew T. Mangino | For The Times The National Commission on COVID-19 and Criminal Justice issued its interim report looking at ways to reduce the pandemic's impact on jails and prisons as well as the courts and law enforcement. The pandemic has consumed every facet of life across the country and around the world Continue reading

Posted in Myocardial Infarction | Comments Off on Matthew T. Mangino: Commission reports on COVID-19 and criminal justice – The Times

Effect of exercise training for five years on all cause mortality in older adultsthe Generation 100 study: randomised controlled trial – The BMJ

Posted: Published on October 8th, 2020

Abstract Objective To evaluate the effect of five years of supervised exercise training compared with recommendations for physical activity on mortality in older adults (70-77 years). Design Randomised controlled trial. Setting General population of older adults in Trondheim, Norway Continue reading

Posted in Myocardial Infarction | Comments Off on Effect of exercise training for five years on all cause mortality in older adultsthe Generation 100 study: randomised controlled trial – The BMJ

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of…

Posted: Published on October 8th, 2020

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. Continue reading

Posted in Myocardial Infarction | Comments Off on PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of…

Ulcerative Colitis: Adopting the AGA’s Guidelines – Medscape

Posted: Published on October 8th, 2020

This transcript has been edited for clarity. David T Continue reading

Posted in Ulcerative Colitis | Comments Off on Ulcerative Colitis: Adopting the AGA’s Guidelines – Medscape

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod – PRNewswire

Posted: Published on October 8th, 2020

STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis Continue reading

Posted in Ulcerative Colitis | Comments Off on The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod – PRNewswire

‘I would rather have died’: How getting a stoma bag changed my life – and broke the stigma – Sky News

Posted: Published on October 8th, 2020

Sarah Smith always said she would rather die than have a stoma bag. After she was diagnosed with ulcerative colitis at 16, she battled painful and "embarrassing" symptoms with heavy medication for more than 10 years. Her condition, which causes the colon and rectum to become inflamed, meant she would regularly have to leave parties or meet-ups with friends suddenly to make sure she didn't have an "accident". Continue reading

Posted in Ulcerative Colitis | Comments Off on ‘I would rather have died’: How getting a stoma bag changed my life – and broke the stigma – Sky News

Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Ulcerative…

Posted: Published on October 8th, 2020

Oct. 2, 2020 10:59 UTC NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Monday, October 12, 2020 at 8:00 a.m. EDT to discuss results from the Phase 3 True North trial evaluating Zeposia (ozanimod) in patients with moderate to severe ulcerative colitis, which will be presented at United European Gastroenterology (UEG) Week 2020 Continue reading

Posted in Ulcerative Colitis | Comments Off on Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Ulcerative…

Page 581«..1020..580581582583..590600..»